Brief: UNITY Biotechnology Gives Positive 48-Week Results From Phase 2 BEHOLD Study Of UBX1325
24/04/2023 12:26
April 24 (Reuters) - UNITY Biotechnology Inc UBX.O :
* UNITY BIOTECHNOLOGY ANNOUNCES POSITIVE 48-WEEK RESULTS
FROM
PHASE 2 BEHOLD STUDY OF UBX1325 IN PATIENTS WITH DIABETIC
MACULAR EDEMA
* UNITY BIOTECHNOLOGY- SINGLE INJECTION OF UBX1325 LED TO
STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL IMPROVEMENT IN
BEST CORRECTED VISUAL ACUITY
* UNITY BIOTECHNOLOGY INC - ABOUT 53% OF UBX1325-TREATED
PATIENTS
DID NOT REQUIRE ANY ADDITIONAL INJECTIONS THROUGH 48 WEEKS
* UNITY BIOTECHNOLOGY INC - UBX1325 HAD A FAVORABLE SAFETY
AND
TOLERABILITY PROFILE WITH NO EVIDENCE OF INTRAOCULAR
INFLAMMATION
Source text for Eikon: ID:nGNX7lC2fp
Further company coverage: UBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Unity Biotechnology
See all newsU.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
Unity Biotechnology slips as co faces Nasdaq delisting, plans dissolution
Brief: Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
Brief: UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force